JP4699027B2 - 新規なアリール−｛４−ハロ−４−〔（ヘテロアリールメチルアミノ）メチル〕ピペリジン−１−イル｝メタノン誘導体、その製造方法および医薬としてのその使用 - Google Patents

新規なアリール−｛４−ハロ−４−〔（ヘテロアリールメチルアミノ）メチル〕ピペリジン−１−イル｝メタノン誘導体、その製造方法および医薬としてのその使用 Download PDF

Info

Publication number
JP4699027B2
JP4699027B2 JP2004513281A JP2004513281A JP4699027B2 JP 4699027 B2 JP4699027 B2 JP 4699027B2 JP 2004513281 A JP2004513281 A JP 2004513281A JP 2004513281 A JP2004513281 A JP 2004513281A JP 4699027 B2 JP4699027 B2 JP 4699027B2
Authority
JP
Japan
Prior art keywords
methyl
piperidin
methanone
fluoro
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004513281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005534668A (ja
JP2005534668A5 (enExample
Inventor
ベルナール、バシェ
ベルナール、ボノー
ジャン‐ルイ、モーレル
フランシス、コルパエール
Original Assignee
ピエール、ファーブル、メディカマン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピエール、ファーブル、メディカマン filed Critical ピエール、ファーブル、メディカマン
Publication of JP2005534668A publication Critical patent/JP2005534668A/ja
Publication of JP2005534668A5 publication Critical patent/JP2005534668A5/ja
Application granted granted Critical
Publication of JP4699027B2 publication Critical patent/JP4699027B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2004513281A 2002-06-18 2003-06-18 新規なアリール−｛４−ハロ−４−〔（ヘテロアリールメチルアミノ）メチル〕ピペリジン−１−イル｝メタノン誘導体、その製造方法および医薬としてのその使用 Expired - Lifetime JP4699027B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR02/07470 2002-06-18
FR0207470A FR2840900B1 (fr) 2002-06-18 2002-06-18 Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments
PCT/FR2003/001873 WO2003106449A1 (fr) 2002-06-18 2003-06-18 Nouveaux derives d'aryl-{4-halogeno-4-[heteroaryl-methylamino)-methyl]-piperidin-1-yl}-methanone, leur procede de preparation et leur utilisation a titre de medicaments

Publications (3)

Publication Number Publication Date
JP2005534668A JP2005534668A (ja) 2005-11-17
JP2005534668A5 JP2005534668A5 (enExample) 2006-08-10
JP4699027B2 true JP4699027B2 (ja) 2011-06-08

Family

ID=29595331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004513281A Expired - Lifetime JP4699027B2 (ja) 2002-06-18 2003-06-18 新規なアリール−｛４−ハロ−４−〔（ヘテロアリールメチルアミノ）メチル〕ピペリジン−１−イル｝メタノン誘導体、その製造方法および医薬としてのその使用

Country Status (14)

Country Link
US (1) US7547700B2 (enExample)
EP (1) EP1539738B1 (enExample)
JP (1) JP4699027B2 (enExample)
CN (1) CN1308325C (enExample)
AT (1) ATE424396T1 (enExample)
AU (1) AU2003258816B2 (enExample)
BR (1) BRPI0311976B8 (enExample)
CA (1) CA2489723C (enExample)
DE (1) DE60326468D1 (enExample)
ES (1) ES2321927T3 (enExample)
FR (1) FR2840900B1 (enExample)
MX (1) MXPA05000024A (enExample)
WO (1) WO2003106449A1 (enExample)
ZA (1) ZA200500467B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2852244B1 (fr) 2003-03-13 2007-09-07 Pf Medicament Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene
FR2891274B1 (fr) * 2005-09-27 2007-11-23 Pierre Fabre Medicament Sa Procede de preparation du (3-chloro-4-fluoro-phenyl)-(4- fluoro-4-{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}- piperidin-1-yl)-methanone et nouveaux derives pyrimidiniques intermediaires.
CA2724737A1 (en) * 2008-05-19 2009-11-26 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
US8389534B2 (en) * 2008-05-19 2013-03-05 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
FR2946344B1 (fr) * 2009-06-05 2012-05-25 Pf Medicament Nouveaux derives d'aryl-{4-halogeno-4-[aminomethyl]-piperidin-1-yl} methanone, leur procede de preparation et leur utilisation a titre de medicaments
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
US10626105B2 (en) 2016-09-22 2020-04-21 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
WO2019016357A1 (en) 2017-07-20 2019-01-24 Neurolixis USE OF SELECTIVE 5-HT1A SEROTONIN RECEPTOR AGONISTS TO TREAT THE ADVERSE EFFECTS OF VMAT INHIBITORS
WO2023144166A1 (en) 2022-01-26 2023-08-03 Neurolixis Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN169588B (enExample) * 1986-10-07 1991-11-16 Pfizer Hospital Prod
FR2755967B1 (fr) * 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
FR2784378B1 (fr) * 1998-10-09 2000-12-29 Pf Medicament Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments
FR2820743B1 (fr) * 2001-02-09 2005-02-25 Pf Medicament Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine

Also Published As

Publication number Publication date
CN1308325C (zh) 2007-04-04
ES2321927T3 (es) 2009-06-15
BRPI0311976B1 (pt) 2015-08-18
AU2003258816A1 (en) 2003-12-31
HK1075452A1 (en) 2005-12-16
ATE424396T1 (de) 2009-03-15
US20060100244A1 (en) 2006-05-11
AU2003258816B2 (en) 2008-08-21
WO2003106449A8 (fr) 2005-02-17
JP2005534668A (ja) 2005-11-17
CA2489723C (fr) 2011-08-02
DE60326468D1 (de) 2009-04-16
FR2840900B1 (fr) 2005-02-25
BR0311976A (pt) 2005-03-29
CA2489723A1 (fr) 2003-12-24
BRPI0311976B8 (pt) 2021-05-25
CN1675194A (zh) 2005-09-28
EP1539738B1 (fr) 2009-03-04
US7547700B2 (en) 2009-06-16
FR2840900A1 (fr) 2003-12-19
ZA200500467B (en) 2005-12-28
WO2003106449A1 (fr) 2003-12-24
EP1539738A1 (fr) 2005-06-15
MXPA05000024A (es) 2005-04-08

Similar Documents

Publication Publication Date Title
AU661527B2 (en) Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
TW200403224A (en) Novel compounds
TWI237023B (en) Benzoxazinone derivatives, their preparation and use
WO2003013510A1 (en) 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
JP2005518414A (ja) ドーパミン受容体のモジュレーターとしての７−スルホニル−３−ベンゾアゼピン誘導体およびｃｎｓ障害の治療のためのその使用
KR101920472B1 (ko) 오렉신 수용체 길항제로서의 피페리딘 유도체
AU7411800A (en) New phenylpiperazines
MXPA02006499A (es) Derivados de fenilpiperazinilo.
JP4699027B2 (ja) 新規なアリール−｛４−ハロ−４−〔（ヘテロアリールメチルアミノ）メチル〕ピペリジン−１−イル｝メタノン誘導体、その製造方法および医薬としてのその使用
JPH05194441A (ja) 新規な置換３−ピペラジニルアルキル−２，３−ジヒドロ−４ｈ−１，３−ベンゾオキサジン−４−オン、その製造法および治療用途
AU772978B2 (en) New benzenesulphonamide compounds, a process for their preparation and pharmaceutical compositions containing them
KR20010041341A (ko) 벤질피페라지닐 및 벤질피페리디닐 에탄온 유도체, 이의제조 방법 및 도파민 ｄ４ 수용체 길항제로서의 이의 용도
JPH04338389A (ja) 置換環式スルファミド誘導体
IE59201B1 (en) Pyridinylpiperazine derivatives
KR102700883B1 (ko) 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의 고체 형태
WO1999021848A2 (en) Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
CA2575785A1 (en) 5-ht7 receptor antagonists
WO1997028157A1 (fr) Nouveaux derives de la piperidine substitues en position 4 par un groupe imidazolidin-2-on-1-yl-ethyl, tetrahydropyrimidin-2-on-1-yl-ethyl, et 1,3-dia-zepin-2-on-1-yl-ethyl, et leurs applications comme antagonistes des recepteurs alpha-2 adrenergiques
HUP0202286A2 (hu) Új benzolszulfonamid-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
CA2171782A1 (en) Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
EP1630158A1 (en) 5-HT7 receptor antagonists
PT1458703E (pt) Compostos isocromano para o tratamento de perturbações do snc
ZA200209886B (en) Indole derivatives useful for the treatment of CNS disorders.
BG108538A (bg) Нови индолови производни
MXPA00005428A (es) Nuevas arilpiperacinilalquil-3 (2h)-piridacinonas.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100311

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100414

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100514

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110302

R150 Certificate of patent or registration of utility model

Ref document number: 4699027

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term